AB Science FDA communication
A very good news for patient Masitinib Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis from FDA
Elucidate the differential vulnerability of motoneurons
Identification of pathways of degeneration and protection in ALS using oculomotor neuron resistance as a tool. Eva Hedlund, associate professor in the department of Neuroscience at Karolinska Institute in Sweden and Stefania Corti associate professor in the Neurology unit...
Discovery of a mediator of microglial function involved in ALS progression
Following the project selected in 2009 by the Thierry Latran Foundation : Study of the pathological neuro-immune interactions between the macrophages/microglial cells and the affected motor neurons in animal models of ALS ( PI Séverine Boillée, Sorbonne Universités, UPMC...
Role of the motor cortical area in ALS
Results making a significant contribution to understand the mechanisms of ALS neurodegeneration, and may providing insights to identify new targets for possible therapeutic manipulations Following the project selected in 2011 by the Thierry Latran Foundation : What is the...
Destruction of motor neurons
Several cellular mechanisms are suspected of causing the destruction of motor neurons Excitotoxicity: a mechanism of alteration and destruction of neurons by an excitatory substance called glutamic acid, present in the body. This mechanism is linked to a certain...
Epidemiology and Genetics
ALS generally appears between the ages of 40 and 70, but can also affect adults older or younger and, in rare cases, adolescents. Compared to other neurodegenerative diseases, the number of victims at a given moment in a given...
Biomarkers in ALS – June 2011
Interest and development of biomarkers in Amyotrophic Lateral Sclerosis The Thierry Latran Foundation is pleased to make available scientific information written and selected by Committee of French neurologists that we strongly thank for their support to the Foundation. NB:...
Highlights 21st International Symposium on ALS
The Thierry Latran Foundation is pleased to provide scientific information selected by a group of French neurologist. The Foundation expresses warm thanks to them for their support. NB: Translation done by the Foundation Highlights 21st International Symposium on ALS/MND...
ALS treatment
Riluzole is the only therapy to have proven any efficacy. Studied since 1996, its efficacy remains moderate with an increase in survival time counted in months. Therefore, treatment is essentially symptomatic: Physiotherapy and occupational therapy (including specific equipment designed...
Symptoms
The onset of ALS is often very subtle, so that the symptoms may initially be overlooked. The earliest symptoms are muscle weakness and/or muscle atrophy. ALS does not usually present itself in a rough manner; the first symptoms, often...